Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The main aim of this study is to evaluate the safety and tolerability of afatinib in patients
with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Epidermal
Growth Factor Receptor (EGFR) mutation(s) and have never been treated with an EGFR-Tyrosine
Kinase Inhibitor (TKI)